semaglutide news october 16 2025 Semaglutide: The Drug of Today and a Steppingstone to Tomorrow Impact of CVS GLP-1 formulary

Put it all together real competition, dropping prices and the GLP-1 dynamic is looking much more like market economics than is usually seen in health care

Weekly injections are often recommended initially, with the option to transition to monthly maintenance treatments

Research shows that those taking tirzepatide medications like Zepbound lost an average of about 21% of their body weight , while those taking Wegovy lost around 15% on average, up to about 19% with the new high-dose 7.2 mg

Try the 3-3-3 Method

In addition, people experiencing typical agerelated cognitive changes may become concerned that the changes are signs of Alzheimer's disease

The FDA updated semaglutide labeling in 2023 to add language about the risk of ileus, following adverse event reports